Kevin Slawin, MD, is the Founder and Managing Partner of Rapha Capital Management. See contact routes.
Kevin Slawin, MD, is the Founder and Managing Partner of Rapha Capital Management, a venture capital firm he established in 2018 after transitioning from his career as an oncologic and robotic surgeon. His investment thesis targets early-stage life science companies, specifically focusing on oncology, T-cell immunotherapy, medical devices, diagnostics, and longevity therapeutics. Rapha Capital seeks to secure investment leads, typically at Series A or just before, through its $100M BioVentures Fund I dedicated to early-stage science. Notable portfolio companies include Bellicum Pharmaceuticals, which Slawin founded and led to a $161 million IPO in 2014, as well as 3DBio Therapeutics and FIZE Medical, where he serves on corporate boards. Slawin also founded AsclepiX Therapeutics, serving as a board member and interim CEO, and invested in FIZE Medical’s $5 million Series A round. His distinctive point of view leverages deep clinical expertise in oncology to identify disruptive technologies in cell control and anti-aging applications.
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in Florida.
Investors like Kevin Slawin · Full investor directory · Investor access · Company funding database